FDA Panel Protects Yaz Profits Over Women’s Safety

Ennis & Ennis, P.A. Explains FDA Advisory Committee Meeting Outcome Regarding Yaz and Yasmin (PRWEB) December 13, 2011 The US Food and Drug Administration (FDA) advisory committee voted 21-5 on Thursday that labeling on Bayer's popular Yaz and similar birth control pills is inadequate and should be revised to better reflect the higher risk of blood clots associated with these drugs, compared with older oral contraceptives. Ennis & Ennis, P.A. explains the panelists want the label to make clearer the potential risk of blood clots in the legs and lungs from taking the pills, and tha
Contributor
PR Web
PR Web
Lanham, Maryland
Law Marketing
1.800.345.5572
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Download

Related Documents in PR Web
MCLE Sales

Categories